Patent application number | Description | Published |
20090047319 | Pharmaceutical composition for obstructive vascular disease - Provided is the excellent prevention or treatment of a vascular occlusive disease such as vascular restenosis. A pharmaceutical composition for a obstructive vascular disease comprising a nucleic acid construct capable of inhibiting the expression of a midkine gene through RNA interference and a collagen molecule. The use of the nucleic acid construct capable of inhibiting the expression of an MK protein through RNA interference in the presence of the collagen molecule can provide an excellent inhibitory effect on the thickened vascular intima. | 02-19-2009 |
20100056437 | Compositions for Treating or Preventing Myocardial Damage or Heart Failure - The present inventors compared myocardial damages after ischemia/reperfusion in wild-type mice and Midkine (MK)-deficient mice to confirm the effects and functions of MK. MK administration was found to significantly prevent cardiomyocyte apoptosis in both cultured cardiomyocytes (in vitro) and mouse models (in vivo). | 03-04-2010 |
20110059508 | IMPROVING AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND RHO KINASE ACTIVATION INHIBITOR - An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. | 03-10-2011 |
20110125075 | METHOD FOR CONTROL OF ELECTROPORATION APPARATUS - A method for controlling an electroporation apparatus for use in an animal such as human and a non-human animal, the method comprising a step of applying a voltage to an electrode of the electroporation apparatus placed in/on a biological sample of the animal in the presence of a nucleic acid construct capable of inhibiting the expression of a gene in the animal. In this manner, a nucleic acid construct can be introduced into a cell of a living body with good efficiency. | 05-26-2011 |
20110275137 | IMPROVING AGENT FOR NEUROPATHIC PAIN - An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan. | 11-10-2011 |
20130164276 | AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND Rho KINASE ACTIVATION INHIBITOR - An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. | 06-27-2013 |
20130230509 | AGENT FOR NEUROPATHIC PAIN - An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan. | 09-05-2013 |
20150353933 | APTAMER AGAINST MIDKINE AND APPLICATIONS THEREOF - The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): | 12-10-2015 |